Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis

To perform this meta-analysis, we investigated the risk of the most clinically relevant adverse events related to antivascular endothelial growth factor receptor (VEGFR) agents in advanced nonsmall-cell lung cancer (NSCLC). A comprehensive literature search for studies published up to October 2015 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Biao, Gao, WenChuang, Chu, HongJun, Gao, Jian, Fu, Zhi, Ding, Hui, Lv, JunJie, Wu, QingQuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134808/
https://www.ncbi.nlm.nih.gov/pubmed/27902583
http://dx.doi.org/10.1097/MD.0000000000003752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134808/
https://www.ncbi.nlm.nih.gov/pubmed/27902583
http://dx.doi.org/10.1097/MD.0000000000003752

Ejemplares similares